Database

ATLANGRAM

Solution provided
TechnologyMarketing
Supplier identity
General description

Research & Development in Biotechnology and Post-Market Studies

Type of Supplier
Service Provider - CMO / CROBiotechnology R&D Company - Diagnostics / Devices and Diagnostics Services
Sector of activity
  • Business development
  • Business Services
  • Animal models
  • Bacteriology
  • Drug Discovery / Research & Development
Region
Regions of Pays de la Loire, Centre and Poitou-Charentes, FR
Regional access broker
  • Grégory Bauer, Atlanpole Biotherapies
Activity description
The 3 top equipments available

ATLANGRAM is a Research and Development Company specialiSed in the evaluation and optimiSation of antimicrobials. ATLANGRAM is interested in developing cooperative and collaborative relationships by conducting in vitro (determination of MICs, MBCs, FIC index; Time&ndash;Kill Curves; Post Antibiotic Effect; Biofilm and biomaterial studies&hellip;) and <em>in vivo</em> studies (on different experimental models of endocarditis, pneumonia, bone infection, arthritis, peritonitis, sepsis&hellip;).
ATLANGRAM uses a software to simulate human pharmacokinetics in animals so the control of programmed administration of antibiotics in animal generates a serum pharmacokinetics superimposable to that of humans and the results are well better extrapolated to human therapeutics.
<p>ATLANGRAM has <strong>a bank of bacterial hospital and community strains</strong>.</p>
<p>ATLANGRAM is based in FRANCE at the Nantes Faculty of Medicine. ATLANGRAM works closely with Nantes Hospital&rsquo;s and University&rsquo;s teamsPre-clinical and biomedical research dedicated to evaluation and optimization of antibiotics use and effects.</p>
<p>For more information, please don&#39;t hesitate to visit our website www.atlangram.com</p>

Know-how, expertise available

 

Therapeutic Efficacy Models

*  Rabbit Pneumonia Model: P. aeruginosa

Rabbit Endocarditis Model: E. faecalis, S. aureus (MRSA, MSSA), P. aeruginosa, E. coli, K. pneumonie, Enterobacter, Serratia, Corynebacterium

Rabbit Osteomyelitis Model: S. aureus (MRSA)

Mouse Pneumonia Model:  P. aeruginosa, S. aureus (MRSA,MSSA), A. baumannii

Mouse urinary Tract Infection:  E. coli

* Mouse Peritonitis / Sepsis: Gram +, Gram - 

Mouse Thigh Infection: : S. aureus, E. coli, K. pneumoniae               

In vivo Parameters

* Human pharmacokinetic simulation: rabbit

* Levels:  plasma, tissues, fluids

* ED50 determination: peritonitis/sepsis

* Appropriate frequency and/or dose administration

* Survival and/or CFU endpoints

* Cytokines quantification: TNF-α, IL 1β, MIP-2

* Myeloperoxydase activity

In vitro antimicrobial and Biofilm assays

* Determination of MICs, MBCs, MPC, PAE, Killing Curves

* Combinations studies: FIC index, Time-Kill & Dynamic checkerboard methods

* Biofilm activity: MICs, Time-Kill studies

Nanoparticles, phages, biomaterials loaded with antibiotics

Ex vivo activity in complex media type fibrin clots

 

Possibilities of partnership

ATLANGRAM is interested in developing cooperative and collaborative relationships by conducting in vitro (determination of MICs, MBCs, FIC index; Time&ndash;Kill Curves; Post Antibiotic Effect; Biofilm and biomaterial studies&hellip;) and <em>in vivo</em> studies (on different experimental models of endocarditis, pneumonia, bone infection, arthritis, peritonitis, sepsis&hellip;)

Services provided

 

Therapeutic Efficacy Models

*  Rabbit Pneumonia Model: P. aeruginosa

*  Rabbit Endocarditis Model: E. faecalis, S. aureus (MRSA, MSSA), P. aeruginosa, E. coli, K. pneumonie, Enterobacter, Serratia, Corynebacterium

*  Rabbit Osteomyelitis Model: S. aureus (MRSA)

*  Mouse Pneumonia Model:  P. aeruginosa, S. aureus (MRSA,MSSA), A. baumannii

*  Mouse urinary Tract Infection:  E. coli

Mouse Peritonitis / Sepsis: Gram +, Gram - 

*  Mouse Thigh Infection: : S. aureus, E. coli, K. pneumoniae               

In vivo Parameters

* Human pharmacokinetic simulation: rabbit

* Levels:  plasma, tissues, fluids

* ED50 determination: peritonitis/sepsis

* Appropriate frequency and/or dose administration

* Survival and/or CFU endpoints

* Cytokines quantification: TNF-α, IL 1β, MIP-2

* Myeloperoxydase activity

In vitro antimicrobial and Biofilm assays

* Determination of MICs, MBCs, MPC, PAE, Killing Curves

* Combinations studies: FIC index, Time-Kill & Dynamic checkerboard methods

* Biofilm activity: MICs, Time-Kill studies

Nanoparticles, phages, biomaterials loaded with antibiotics

Ex vivo activity in complex media type fibrin clots

Training and Staff possibilities
No
Contact information
Name
REGHAL
Surname
Amokrane
Function
CEO
Phone number
+33 (0)2 36 56 90 01
Address
1 rue Gaston Veil
UFR Médecine
44035  Nantes
France